Develops drugs for acute myeloid leukemia and soft tissue sarcoma.
Jun 2026Revenue $0.00/yrExpenses $28.9M/yr
No trendCash runway ≈ 3 months from Jun 2026
Figures by year
When will Moleculin Biotech be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $0.00 and expenses $28.9M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $0.00 | $25.1M | −$25.1M |
| Dec 2024 | $0.00 | $26.6M | −$26.6M |
| Dec 2023 | $0.00 | $29.6M | −$29.6M |
| Dec 2022 | $0.00 | $30.6M | −$30.6M |
| Dec 2021 | $0.00 | $23.0M | −$23.0M |
| Dec 2020 | $0.00 | $19.7M | −$19.7M |
| Dec 2019 | $0.00 | $17.5M | −$17.5M |
| Dec 2018 | $0.00 | $15.0M | −$15.0M |
| Dec 2017 | $0.00 | $8.65M | −$8.65M |
| Dec 2016 | $0.00 | $3.88M | −$3.88M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.